TetraPhase Pharmaceuticals To Present Research At ICAAC On Its Novel Chemistry Platform’s Ability To Address Antibiotic Resistance

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that nine posters and one oral presentation on data related to the Company’s next-generation antibiotics portfolio – including its lead candidate eravacycline that is currently in Phase 3 clinical development for treatment of bacterial infections including multidrug-resistant (MDR) infections – will be presented at the upcoming 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

Help employers find you! Check out all the jobs and post your resume.